Biomea Fusion, Inc. (BMEA)
1.42
+0.05
(+3.65%)
USD |
NASDAQ |
Oct 09, 16:00
1.415
0.00 (0.00%)
After-Hours: 20:00
Biomea Fusion Cash from Operations (Quarterly) : -10.03M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -10.03M |
| March 31, 2026 | -11.67M |
| December 31, 2025 | -13.19M |
| September 30, 2025 | -12.18M |
| June 30, 2025 | -19.33M |
| March 31, 2025 | -25.67M |
| December 31, 2024 | -30.00M |
| September 30, 2024 | -25.22M |
| June 30, 2024 | -32.64M |
| March 31, 2024 | -32.03M |
| December 31, 2023 | -22.84M |
| September 30, 2023 | -23.90M |
| June 30, 2023 | -25.81M |
| Date | Value |
|---|---|
| March 31, 2023 | -24.04M |
| December 31, 2022 | -20.20M |
| September 30, 2022 | -16.80M |
| June 30, 2022 | -15.43M |
| March 31, 2022 | -9.994M |
| December 31, 2021 | -15.90M |
| September 30, 2021 | -8.988M |
| June 30, 2021 | -6.476M |
| March 31, 2021 | -4.075M |
| December 31, 2020 | -2.736M |
| September 30, 2020 | -1.102M |
| June 30, 2020 | -0.369M |
| March 31, 2020 | -0.252M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| REGENXBIO, Inc. | -62.24M |
| Compass Therapeutics, Inc. | -14.74M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
| Anika Therapeutics, Inc. | -0.684M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Financing (Quarterly) | 0.159M |
| Free Cash Flow | -47.06M |
| Free Cash Flow Per Share (Quarterly) | -0.1386 |
| Free Cash Flow to Equity (Quarterly) | -9.666M |
| Free Cash Flow to Firm (Quarterly) | -10.03M |
| Free Cash Flow Yield | -47.89% |